Affiliation:
1. Southwest Hospital, Third Military Medical University (Army Medical University, Ministry of Education of China
2. Army 953 Hospital, Third Military Medical University (Army Medical University)
3. Third Military Medical University (Army Medical University)
Abstract
Abstract
Gliomas are not only among the most vascular-rich solid tumors, but also the most common primary brain tumors. The vascular morphology and molecular characteristics of gliomas are heterogeneous. Pericytes are one of the important cell components in glioma vascular structure and are highly heterogenies. However, the heterogeneity of pericytes in gliomas is not clear, and the biological characteristics and clinical significance of different subpopulations of pericytes are still unknown. An in-depth understanding of pericyte characteristics based on gene expression profiling, as well as the correlation of pericytes and the clinical prognosis of glioma are important prerequisites for the development of follow-up targeted vascular therapy. In this study, the heterogeneity of pericytes in glioma was revealed by single-cell RNA sequencing technique, the relationship between pericyte subpopulations and patient survival, prognosis and treatment response were clarified, and the MMP9+ pericytes were identified as a unique pericyte subpopulation in the core area of glioma, providing theoretical basis for analyzing the characteristics of vascular microenvironment of glioma and new targets for anti-vascular therapy of glioma.
Publisher
Research Square Platform LLC
Reference45 articles.
1. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. Neuro-oncology 20(suppl_4):iv1-iv86. https://doi:10.1093/neuonc/noy131
2. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment;Tellingen O;Drug Resist updates: reviews commentaries Antimicrob anticancer Chemother,2015
3. Dynamics of CNS barriers: evolution, differentiation, and modulation;Abbott NJ;Cell Mol Neurobiol,2005
4. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook;Garcia J;Cancer Treat Rev,2020
5. Current status and future directions of anti-angiogenic therapy for gliomas;Wick W;Neurooncology,2016